Real-world calibration and transportability of the Disease Recovery Evaluation and Modification (DREaM) randomized clinical trial in adult Medicaid beneficiaries with recent-onset schizophrenia

BACKGROUND: The Disease Recovery Evaluation and Modification study (DREaM; NCT02431702) assessed the benefit of initiating paliperidone palmitate (PP), a long-acting injectable antipsychotic, in patients with recent-onset schizophrenia or schizophreniform disorder. OBJECTIVE: To determine whether re...

Descripción completa

Detalles Bibliográficos
Autores principales: Basu, Anirban, Patel, Charmi, Fu, Alex Z, Brown, Brianne, Mavros, Panagiotis, Benson, Carmela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394194/
https://www.ncbi.nlm.nih.gov/pubmed/36692909
http://dx.doi.org/10.18553/jmcp.2023.22191

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394194/
https://www.ncbi.nlm.nih.gov/pubmed/36692909
http://dx.doi.org/10.18553/jmcp.2023.22191

Ejemplares similares